Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA neurology"
DOI: 10.1001/jamaneurol.2022.0315
Abstract: Importance Several anti-amyloid monoclonal antibodies have been developed for slowing the progression of Alzheimer disease (AD). Among the furthest developed are aducanumab, which received accelerated approval from the US Food and Drug Administration in 2021,… read more here.
Keywords: disease; donanemab; cost effectiveness; aducanumab ... See more keywords
Analyses à 48 mois de PRIME, une étude de phase 1b chez des patients atteints de la maladie d’Alzheimer au stade précoce, utilisant l’aducanumab
Sign Up to like & getrecommendations! Published in 2019 at "Revue Neurologique"
DOI: 10.1016/j.neurol.2019.01.052
Abstract: Introduction PRIME est une etude de phase 1b en cours evaluant la securite, la tolerance, la pharmacocinetique et la pharmacodynamique de l’aducanumab chez des patients atteints d’une maladie d’Alzheimer (MA) precoce [1] . Objectifs Analyses… read more here.
Keywords: aducanumab; patients atteints; chez des; phase ... See more keywords
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Sign Up to like & getrecommendations! Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-24501-0
Abstract: Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical trials for the treatment of Alzheimer’s disease. Biochemical and structural analyses show that aducanumab binds a linear epitope formed by amino acids 3–7… read more here.
Keywords: structural kinetic; aducanumab; kinetic basis; epitope ... See more keywords
Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2021 at "Aging and Disease"
DOI: 10.14336/ad.2021.0719
Abstract: Alzheimer’s disease (AD) is the leading cause of dementia that has remained a major medical, sociocultural and economical challenge globally. Previously developed treatments like anticholinesterase inhibitors (AChEIs) and N-methyl-D-aspartate receptor (NMDAR) antagonists only provide short-term… read more here.
Keywords: aducanumab; pioglitazone; disease comparative; alzheimer disease ... See more keywords